ResearcherHumboldt-Universität zu BerlinNo recent work listed
Fritz Klein
Matched on ORCID iD 0000-0002-8940-6001; OpenAlex author ID A5029124437, A5061530886. Sources: OpenAlex.
Their work
- Papers
- 14 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 38
2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 2 papers · 2016: none · 2017: 2 papers · 2018: 4 papers · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper
Papers 14
- Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancr… Co-author DOI 10.1053/j.gastro.2022.07.047↗
- Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells10071821↗
- Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma-Who Will Benefit from a Secondary Resection? Co-author DOI 10.3390/medicina57010077↗
- Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis. Co-author DOI 10.21873/anticanres.13781↗
- Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospecti… Co-author DOI 10.1016/j.ejca.2018.06.001↗
- Routine portal vein resection for pancreatic adenocarcinoma shows no benefit in overall survival. Co-author DOI 10.1016/j.ejso.2018.05.002↗
- The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. Co-author DOI 10.1016/j.suronc.2018.09.004↗
- Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-018-0093-y↗
- Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients. Co-author DOI 10.1371/journal.pone.0186341↗
- Incidence and Oncological Implications of Previously Undetected Tumor Multicentricity Following Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in Patien… First author DOI 10.21873/anticanres.11952↗
- Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer. Co-author DOI 10.1002/jso.23951↗
- Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy. Co-author DOI 10.1097/mpa.0000000000000365↗
- Blood group determinates incidence for pancreatic cancer in Germany. First author DOI 10.3389/fphys.2013.00118↗
- The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma. Co-author DOI 10.1155/2012/939350↗
Closest collaborators
The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Marcus Bahra · 11 shared papers, 2012–2021 · strength 0.79
- Paper Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma-Who Will Benefit from a Se… DOI 10.3390/medicina57010077↗
- Paper Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreati… DOI 10.21873/anticanres.13781↗
- Paper Routine portal vein resection for pancreatic adenocarcinoma shows no benefit in overall survival. DOI 10.1016/j.ejso.2018.05.002↗
- Uwe Pelzer · 11 shared papers, 2012–2021 · strength 0.79
- Paper Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma-Who Will Benefit from a Se… DOI 10.3390/medicina57010077↗
- Paper Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreati… DOI 10.21873/anticanres.13781↗
- Paper Routine portal vein resection for pancreatic adenocarcinoma shows no benefit in overall survival. DOI 10.1016/j.ejso.2018.05.002↗
- Marianne Sinn · 7 shared papers, 2013–2018 · strength 0.42
- Paper Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from chole… DOI 10.1016/j.ejca.2018.06.001↗
- Paper Incidence and Oncological Implications of Previously Undetected Tumor Multicentricity Following Pancreaticoduodenectomy… DOI 10.21873/anticanres.11952↗
- Paper Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. DOI 10.1038/s41416-018-0093-y↗
- Thomas Malinka · 4 shared papers, 2018–2021 · strength 0.41
- Paper Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma-Who Will Benefit from a Se… DOI 10.3390/medicina57010077↗
- Paper Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreati… DOI 10.21873/anticanres.13781↗
- Paper Routine portal vein resection for pancreatic adenocarcinoma shows no benefit in overall survival. DOI 10.1016/j.ejso.2018.05.002↗
- Timm Denecke · 5 shared papers, 2015–2018 · strength 0.36
- Paper Routine portal vein resection for pancreatic adenocarcinoma shows no benefit in overall survival. DOI 10.1016/j.ejso.2018.05.002↗
- Paper Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from chole… DOI 10.1016/j.ejca.2018.06.001↗
- Paper Incidence and Oncological Implications of Previously Undetected Tumor Multicentricity Following Pancreaticoduodenectomy… DOI 10.21873/anticanres.11952↗
- Hanno B. Riess · 6 shared papers, 2013–2018 · strength 0.35
- Paper Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from chole… DOI 10.1016/j.ejca.2018.06.001↗
- Paper Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. DOI 10.1038/s41416-018-0093-y↗
- Paper Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and… DOI 10.1371/journal.pone.0186341↗
- Lea Timmermann · 2 shared papers, 2019–2021 · strength 0.25
- Paper Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma-Who Will Benefit from a Se… DOI 10.3390/medicina57010077↗
- Paper Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreati… DOI 10.21873/anticanres.13781↗
- Nathalie Rosumeck · 2 shared papers, 2019–2021 · strength 0.25
- Paper Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma-Who Will Benefit from a Se… DOI 10.3390/medicina57010077↗
- Paper Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreati… DOI 10.21873/anticanres.13781↗
- Ivonne Regel · 2 shared papers, 2021–2022 · strength 0.21
- Elisabetta Goni · 2 shared papers, 2021–2022 · strength 0.21
- Waldemar H. Uhl · 2 shared papers, 2021–2022 · strength 0.21
- Frank Ulrich Weiß · 2 shared papers, 2021–2022 · strength 0.21
- Robert Grützmann · 2 shared papers, 2021–2022 · strength 0.21
- Georg Beyer · 2 shared papers, 2021–2022 · strength 0.21
- Julia V. Mayerle · 2 shared papers, 2021–2022 · strength 0.21
- Markus M. Lerch · 2 shared papers, 2021–2022 · strength 0.21
- Ujjwal Mukund Mahajan · 2 shared papers, 2021–2022 · strength 0.21
- Christian P. Pilarsky · 2 shared papers, 2021–2022 · strength 0.21
- Marius Distler · 2 shared papers, 2021–2022 · strength 0.21
- Jana Käthe Striefler · 3 shared papers, 2015–2018 · strength 0.20
- Paper Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from chole… DOI 10.1016/j.ejca.2018.06.001↗
- Paper Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. DOI 10.1038/s41416-018-0093-y↗
- Paper Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer. DOI 10.1002/jso.23951↗
- Anja Jühling · 2 shared papers, 2018 · strength 0.15
- Andréas Andreou · 2 shared papers, 2017–2018 · strength 0.14
- Rosa Bianca Schmuck · 2 shared papers, 2017–2018 · strength 0.14
- Helmut Oettle · 2 shared papers, 2015–2018 · strength 0.12
- Simon Sirtl · 1 shared paper, 2022 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.